erlotinib hydrochloride has been researched along with calcitriol in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (calcitriol) | Trials (calcitriol) | Recent Studies (post-2010) (calcitriol) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 16,107 | 1,224 | 3,710 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | calcitriol (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0093 | |
| Vitamin D3 receptor | Homo sapiens (human) | 0.3401 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.0093 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Hernandez, D; Arcidiacono, MV; Cannata-Andia, J; Dusso, AS; Gonzalez-Suarez, I; Lu, Y; Sato, T; Slatopolsky, E; Tokumoto, M; Tominaga, Y; Yang, J | 1 |
| Arcidiacono, MV; Dusso, A; Fernandez, E; Yang, J | 1 |
| Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A | 1 |
| Hershberger, PA; Liu, C; Petkovich, M; Shaurova, T; Shoemaker, S; Wu, Y | 1 |
4 other study(ies) available for erlotinib hydrochloride and calcitriol
| Article | Year |
|---|---|
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.
Topics: Animals; Calcitriol; Carcinoma, Squamous Cell; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Renal Insufficiency, Chronic; Transforming Growth Factor alpha | 2008 |
The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcitriol; CCAAT-Enhancer-Binding Protein-beta; Cell Proliferation; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Immunoenzyme Techniques; Kidney Diseases; Parathyroid Glands; Parathyroid Hormone; Rats; Real-Time Polymerase Chain Reaction; Receptors, Calcitriol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor alpha; Vitamin D; Vitamins | 2015 |
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones | 2015 |
Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liposomes; Lung Neoplasms; Mutation; Nanoparticles; Protein Kinase Inhibitors; Vitamin D3 24-Hydroxylase | 2018 |